ArticleiScience2026
A host-centric morphological profiling approach to identify repurposed antiviral drugs.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiviral drug discovery has traditionally targeted viral proteins, while host-directed strategies remain underexplored. We present a systematic drug repurposing strategy that uses morphological profiling to identify host-targeting antivirals. Using cell painting, we demonstrate that SARS-CoV-2 infection can be accurately determined from the morphological profile of virus-infected cells. Moreover, morphological features reveal how host cells respond to viral exposure, offering insights into antiviral activity, host-cell health, and putative mechanisms of action of the compounds. Screening 5,275 repurposable compounds, we identified candidates that reversed the infected phenotype, including ones not detected by conventional cytopathicity and antibody-based assays. After deprioritization of confounding phospholipidosis, we present 74 hit candidates, including unreported compounds targeting host processes implicated in viral infection. This adaptable and scalable platform is suited for diverse viruses and cell systems. We provide a resource of open-access screening data, images, and analysis pipelines to advance antiviral discovery and pandemic preparedness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.